Fierce Biotech7d
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Hosted on MSN1mon
Hypoparathyroidism
Primary hypoparathyroidism is a disease of the parathyroid glands, while secondary hypoparathyroidism results from damage to the glands. Sometimes there is no identifiable cause, and the condition ...
Clinical Trials Arena on MSN6d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
Baylor College of Medicine1y
Scarless Thyroid and Parathyroid Surgery
Although other types of thyroid and parathyroid techniques may not leave a scar on the ... than 2 cm Thyroid removal for benign conditions such as goiter or Graves’ disease Benign thyroid nodule less ...
PharmiWeb7d
Eneboparatide met primary endpoint of normalising…
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...